These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8971471)

  • 21. Antisense therapy in malignant diseases: status quo and quo vadis?
    Tamm I
    Clin Sci (Lond); 2006 Apr; 110(4):427-42. PubMed ID: 16526947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploiting genetic alterations to design novel therapies for cancer.
    Cripe TP; Mackall CL
    Hematol Oncol Clin North Am; 2001 Aug; 15(4):657-75, viii. PubMed ID: 11676278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antisense oligonucleotides for cancer therapy-an overview.
    Stahel RA; Zangemeister-Wittke U
    Lung Cancer; 2003 Aug; 41 Suppl 1():S81-8. PubMed ID: 12867066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of protooncogene expression by antisense oligodeoxynucleotides: biological and therapeutic implications.
    Calabretta B
    Cancer Res; 1991 Sep; 51(17):4505-10. PubMed ID: 1873794
    [No Abstract]   [Full Text] [Related]  

  • 25. Prospects for gene-directed therapy with antisense oligodeoxynucleotides.
    Calabretta B; Skorski T; Szczylik C; Zon G
    Cancer Treat Rev; 1993 Apr; 19(2):169-79. PubMed ID: 8481928
    [No Abstract]   [Full Text] [Related]  

  • 26. Antisense of oligonucleotides and the inhibition of oncogene expression.
    Prins J; de Vries EG; Mulder NH
    Clin Oncol (R Coll Radiol); 1993; 5(4):245-52. PubMed ID: 8398922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antisense strategies for oncogene inactivation.
    Stein CA; Benimetskaya L; Mani S
    Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The therapeutic potential of microRNAs in cancer.
    Thorsen SB; Obad S; Jensen NF; Stenvang J; Kauppinen S
    Cancer J; 2012; 18(3):275-84. PubMed ID: 22647365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of antisense oligonucleotide and low-dose chemotherapy in hematological malignancies.
    Benner E; Bishop MR; Agarwal N; Iversen P; Joshi SS
    J Pharmacol Toxicol Methods; 1997 Jun; 37(4):229-35. PubMed ID: 9279778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antisense regulation of oncogenes in human cancer.
    Mukhopadhyay T; Roth JA
    Crit Rev Oncog; 1996; 7(3-4):151-90. PubMed ID: 9258601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of antisense inhibition of Urokinase receptor on malignancy.
    Ossowski L
    Curr Top Microbiol Immunol; 1996; 213 ( Pt 3)():101-12. PubMed ID: 8815000
    [No Abstract]   [Full Text] [Related]  

  • 32. Antisense therapy in clinical oncology: preclinical and clinical experiences.
    Tamm I; Wagner M
    Mol Biotechnol; 2006 Jul; 33(3):221-38. PubMed ID: 16946452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene therapy for cancer.
    Kipps TJ
    J Hematother; 1993; 2(3):367-72. PubMed ID: 7921998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progress in antisense oligonucleotide therapeutics.
    Crooke ST; Bennett CF
    Annu Rev Pharmacol Toxicol; 1996; 36():107-29. PubMed ID: 8725384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perturbing gene expression with oligodeoxynucleotides: research and potential therapeutic applications.
    Gewirtz AM
    Mt Sinai J Med; 1996; 63(5-6):372-80. PubMed ID: 8898543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RNA targeted therapeutics for hematologic malignancies.
    Gewirtz AM
    Blood Cells Mol Dis; 2007; 38(2):117-9. PubMed ID: 17215146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A potential role for antisense oligonucleotide analogues in the development of oncogene targeted cancer chemotherapy.
    Tidd DM
    Anticancer Res; 1990; 10(5A):1169-82. PubMed ID: 2241097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug.
    Pakunlu RI; Wang Y; Saad M; Khandare JJ; Starovoytov V; Minko T
    J Control Release; 2006 Aug; 114(2):153-62. PubMed ID: 16889867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antisense oligodeoxynucleotides for the treatment of chronic myelogenous leukemia: are they still a promise?
    de Fabritiis P; Calabretta B
    Haematologica; 1995; 80(4):295-9. PubMed ID: 7590496
    [No Abstract]   [Full Text] [Related]  

  • 40. Antisense therapy in cancer.
    Pawlak W; Zolnierek J; Sarosiek T; Szczylik C
    Cancer Treat Rev; 2000 Oct; 26(5):333-50. PubMed ID: 11006135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.